Loading...
OTCM
PLPL
, Last price  
USD
Name

Plandai Biotechnology Inc

Chart & performance

D1W1MN
OTCM:PLPL chart
P/E
—
P/B
—
EPS
—
Vol. 1Y
—
Shs. 5Y
76.51%
Rev. 5Y
6.48%
Div Yld LY
—
Div Yld TTM
—
Revenues
0
10,040,00012,815,00012,750,00011,265,0006,416,0008,549,0007,163,00074,452359,143265,74892,898298,494411,9890000000
Net income
-51k
L+2,001.43%
-1,519,000-597,000-979,000-1,894,000-825,000-830,000-548,000-3,777,000-2,188,000-15,607,000-9,582,000-4,379,000-4,008,000-83,481-397,0006,824,000-19,801,00016,029,000-2,446-51,401
CFO
16m
+2,702.25%
-362,472-362,472-1,415,438-580,040-2,539,740-442,019172,150-176,097306,807-796,296-1,776,735-2,593,156-2,703,939-1,071,760-1,097,0600-6,6756,964,996558,11415,639,733

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Plandaí Biotechnology, Inc. does not have significant operations. Previously, it was involved in a biotechnology-related business. Plandaí Biotechnology, Inc. is based in Taipei, Taiwan.

Key people

Chairman of the Board, Chief Executive Officer, Chief Financial Officer · since 2017
Ezra Jones
Vice President of Sales and Marketing · since 2017
Jamen Shively
Vice President - Global Marketing · since 2016
Callum Cottrell Duffield
President, Chief Operating Officer, Vice President of Sales and Marketing, Secretary, Director · since 2017
Daron Baylis Duffield
Director · since 2011
Brian Johnson
Director · since 2011
IPO date
Dec 10, 2001
Employees
180
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2026‑062025‑062024‑062023‑062022‑062021‑062020‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT